Voxmedia22107

In this program, experts in the use of antiplatelet therapy in CAD and acute ischemic stroke/TIA will describe best uses of antiplatelet therapy to optimize clinical outcomes in these settings.

This educational initiative will focus on current insights into use of antiplatelet therapy in individuals with high-risk coronary artery disease (CAD) or who have experienced an acute ischemic stroke/transient ischemic attack (TIA). Strategies with antiplatelet therapy to mitigate bleeding risk after percutaneous coronary intervention (PCI) without increasing the risk of ischemic outcomes will be identified. Settings will also be described where extended duration of dual antiplatelet therapy (DAPT) may provide net clinical benefit. In addition to clinical trial results and updated FDA labeling, current meta-analyses will be interpreted, enabling attendees to have a clearer understanding of the duration of DAPT—benefits and risks associated with short-term DAPT followed by P2Y12 inhibitor therapy, as well as with extended DAPT. Decision-making regarding the use of DAPT is also a critical component of management of patients experiencing an acute ischemic stroke or TIA. Clinicians need to recognize patients eligible for the addition of either clopidogrel or ticagrelor to aspirin (ASA) based on clinical trial evidence, and that timely initiation of DAPT is critical for reduction in risk of recurrent stroke. A common guiding principle for use of antiplatelet therapy in patients with CAD or acute ischemic stroke/TIA is a personalized approach. Therefore, in this program, experts in the use of antiplatelet therapy in CAD and acute ischemic stroke/TIA will describe best uses of antiplatelet therapy to optimize clinical outcomes in these settings.

Login to your Account